Advertisement

Annovis Bio, Inc. ANVS

Set alert

Price alert · ANVS

All alert types
1.13 USD +0.11 +10.78%

At close

1.17 +0.04 +3.54%

Pre-market · Nov 2, 4:02 AM ET

Bid
1.13 × 1,100
Ask
1.14 × 3,400
1.01 Day range 1.17
0.93 52-week range 5.50
YTD
-67.34%
1 year
-45.67%
Open
1.02
Prev close
1.02
Mkt cap
48.23M
Vol
1.48M
Avg vol
902.76K
EPS
-1.75
P/E
0.00
Div yield
0.00%
More statistics
Low
1.01
High
1.17
Forward P/E
-2.77
Beta
0.00
Short ratio
6.21
Inst. own
8.83%
Dividend
0.00
Ex-div date
Earnings
Aug 14, 2024
50-d avg
7.29
200-d avg
8.47
1y target
34.80

5Y chart

Chart tools
Interval

Events in this range
  • Mar 29, 2024Earnings: -1.09; estimate -1.35; surprise 19.26%
  • May 13, 2024Earnings: —; estimate -0.87; surprise —%
  • May 13, 2024Earnings: -0.72; estimate -0.87; surprise 17.24%
  • Aug 13, 2024Rating: EF Hutton · — → Buy
  • Aug 14, 2024Earnings: —; estimate -0.7; surprise —%
  • Aug 14, 2024Earnings: -0.44; estimate -0.7; surprise 37.14%
  • Aug 15, 2024Rating: HC Wainwright & Co. · Buy → Buy
  • Aug 15, 2024Rating: EF Hutton · Buy → Buy
  • Oct 25, 2024Rating: Maxim Group · Hold → Buy
  • Nov 8, 2024Earnings: -0.97; estimate -0.64; surprise -51.56%
  • Nov 11, 2024Rating: HC Wainwright & Co. · Buy → Buy
  • Nov 11, 2024Rating: D. Boral Capital · Buy → Buy
Signals (101)
NameDateAgo
MACD: Sell SignalSep 7, 20261 month ago
SMA: BearishAug 24, 20262 months ago
SMA: BullishAug 3, 20263 months ago
MACD: Buy SignalJul 6, 20263 months ago
SMA: BearishMay 25, 20265 months ago
SMA: BullishMay 18, 20265 months ago
SMA: BearishMay 11, 20265 months ago
SMA: BullishMay 4, 20266 months ago
SMA: BearishJan 26, 20269 months ago
MACD: Sell SignalJan 26, 20269 months ago
SMA: BearishJan 12, 20269 months ago
RSI: OverboughtNov 24, 202511 months ago
SMA: BullishNov 10, 202511 months ago
SMA: BullishNov 10, 202511 months ago
SMA: BearishOct 6, 20251 year ago
SMA: BullishSep 29, 20251 year ago
SMA: BearishSep 22, 20251 year ago
SMA: BearishAug 18, 20251 year ago
SMA: BullishAug 11, 20251 year ago
SMA: BearishJul 28, 20251 year ago
SMA: BullishJul 21, 20251 year ago
SMA: BullishJun 30, 20251 year ago
SMA: BearishJun 23, 20251 year ago
SMA: BullishMay 12, 20251 year ago
SMA: BearishMay 5, 20251 year ago
SMA: BullishApr 28, 20251 year ago
MACD: Buy SignalApr 28, 20251 year ago
RSI: OversoldFeb 17, 20251 year ago
MACD: Sell SignalNov 11, 20241 year ago
SMA: BearishNov 4, 20241 year ago
SMA: BearishNov 4, 20241 year ago
SMA: BullishOct 14, 20242 years ago
SMA: BullishOct 14, 20242 years ago
MACD: Buy SignalOct 14, 20242 years ago
SMA: BearishOct 7, 20242 years ago
MACD: Sell SignalOct 7, 20242 years ago
SMA: BullishSep 30, 20242 years ago
MACD: Buy SignalSep 30, 20242 years ago
MACD: Sell SignalSep 23, 20242 years ago
MACD: Buy SignalSep 16, 20242 years ago
MACD: Sell SignalSep 9, 20242 years ago
SMA: BearishAug 26, 20242 years ago
SMA: BearishAug 26, 20242 years ago
SMA: BullishAug 19, 20242 years ago
SMA: BullishAug 19, 20242 years ago
SMA: BearishAug 5, 20242 years ago
SMA: BearishJul 29, 20242 years ago
MACD: Buy SignalJul 8, 20242 years ago
SMA: BullishJul 1, 20242 years ago
SMA: BullishJul 1, 20242 years ago
SMA: BearishApr 29, 20242 years ago
SMA: BearishApr 29, 20242 years ago
MACD: Sell SignalApr 29, 20242 years ago
SMA: BullishApr 22, 20242 years ago
SMA: BearishApr 15, 20242 years ago
MACD: Buy SignalMar 25, 20242 years ago
SMA: BullishMar 18, 20242 years ago
SMA: BullishMar 18, 20242 years ago
MACD: Sell SignalFeb 26, 20242 years ago
SMA: BearishFeb 12, 20242 years ago
SMA: BullishFeb 5, 20242 years ago
SMA: BearishJan 22, 20242 years ago
SMA: BearishJan 22, 20242 years ago
RSI: OverboughtDec 25, 20232 years ago
SMA: BullishDec 18, 20232 years ago
MACD: Buy SignalDec 4, 20232 years ago
SMA: BullishNov 27, 20232 years ago
RSI: OversoldOct 23, 20233 years ago
RSI: OversoldOct 2, 20233 years ago
SMA: BearishJul 3, 20233 years ago
SMA: BullishJun 12, 20233 years ago
SMA: BearishMay 1, 20233 years ago
SMA: BearishApr 24, 20233 years ago
SMA: BullishApr 17, 20233 years ago
SMA: BullishApr 10, 20233 years ago
SMA: BearishApr 3, 20233 years ago
MACD: Sell SignalApr 3, 20233 years ago
SMA: BearishMar 27, 20233 years ago
SMA: BullishMar 20, 20233 years ago
SMA: BearishMar 6, 20233 years ago
SMA: BullishDec 19, 20223 years ago
SMA: BullishDec 19, 20223 years ago
MACD: Buy SignalDec 19, 20223 years ago
MACD: Sell SignalDec 12, 20223 years ago
SMA: BearishDec 5, 20223 years ago
SMA: BearishNov 28, 20223 years ago
SMA: BullishNov 21, 20223 years ago
SMA: BearishOct 3, 20224 years ago
SMA: BullishSep 5, 20224 years ago
SMA: BullishSep 5, 20224 years ago
SMA: BearishAug 15, 20224 years ago
SMA: BearishAug 15, 20224 years ago
SMA: BullishAug 8, 20224 years ago
SMA: BullishAug 8, 20224 years ago
SMA: BearishJul 25, 20224 years ago
SMA: BearishJul 11, 20224 years ago
SMA: BullishJul 4, 20224 years ago
RSI: OversoldJun 13, 20224 years ago
SMA: BullishJun 6, 20224 years ago
SMA: BearishMar 28, 20224 years ago
SMA: BullishMar 14, 20224 years ago

Key statistics

Market cap
69.12M
Enterprise value
47.66M
Trailing P/E
0.00
Forward P/E
-2.77
PEG ratio
0.00
Price / sales
0.00
Price / book
9.42
EPS (TTM)
-4.22
Beta
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
0
Revenue growth
0.00%
Free cash flow
-11.57M
Total cash
12.64M
Total debt
0
Return on equity
-596.70%
Shares outstanding
13.80M
Short % of float
11.95%
50-day average
7.29
200-day average
8.47

Analyst view

Consensus: buy

Buy
Price target (mean) 34.80 +2979.6% upside
Target (low)
21.00
Target (mean)
34.80
Target (high)
72.00
Ratings (0m) 6 5 buy · 1 hold · 0 sell
  • Strong buy2
  • Buy3
  • Hold1
  • Sell0
  • Strong sell0

Next earnings

Aug 14, 2024

Expected Aug 14, 2024. Consensus EPS estimate -0.20.

Earnings history

Financials — quick view

All financials
ANVS Revenue — quarterly 0
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ANVS Net income — quarterly -14.82M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ANVS EPS — quarterly -0.40
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

ANVS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 8, 2024Sep 1, 2024-0.64-0.97-0.33-51.56%
Aug 14, 2024Jun 1, 2024-0.70———
Aug 14, 2024Jun 1, 2024-0.70-0.44+0.26+37.14%
May 13, 2024Mar 1, 2024-0.87———
May 13, 2024Mar 1, 2024-0.87-0.72+0.15+17.24%
Mar 29, 2024Dec 1, 2023-1.35-1.09+0.26+19.26%

Upgrades / downgrades

ANVS analyst upgrades and downgrades
DateFirmActionFromTo
Nov 11, 2024D. Boral CapitalmainBuyBuy
Nov 11, 2024HC Wainwright & Co.reitBuyBuy
Oct 25, 2024Maxim GroupupHoldBuy
Aug 15, 2024EF HuttonmainBuyBuy
Aug 15, 2024HC Wainwright & Co.reitBuyBuy
Aug 13, 2024EF Huttoninit—Buy

About Annovis Bio, Inc.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on ANVS — it syncs with the Stock Master app.

Insider holders

ANVS insider holders
InsiderRelationLatest transactionDateShares held
BRUCK CLAUDINEDirectorStock Award(Grant)Nov 19, 20237,567
HAGOPIAN HENRY IIIChief Financial OfficerStock Award(Grant)Nov 19, 20231,824
HOFFMAN MICHAEL BDirector and Beneficial Owner of more than 10% of a Class of SecurityStock Award(Grant)Nov 19, 20230
MACCECCHINI MARIA-LUISAChief Executive OfficerStock GiftMar 27, 20241,068,460
MCCARTHY REID S.DirectorStock Award(Grant)Nov 19, 20238,129
WHITE MARK K.DirectorStock Award(Grant)Nov 19, 202361,177

Institution ownership

ANVS institution ownership
Holder% heldSharesValueReported
Vanguard Group Inc2.76%380,2551.91MSep 29, 2024
Blackrock Inc.0.74%101,495508.49KSep 29, 2024
Citadel Advisors Llc0.74%102,692514.49KSep 29, 2024
Geode Capital Management, LLC0.72%99,114496.56KSep 29, 2024
Group One Trading, L.P.0.38%52,767264.36KSep 29, 2024
Quest Partners LLC 0.33%46,002230.47KSep 29, 2024

Fund ownership

ANVS fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.91%263,5071.32MSep 29, 2024
Vanguard Extended Market Index Fund0.80%110,600554.11KSep 29, 2024
Fidelity Extended Market Index Fund0.40%55,356277.33KOct 30, 2024
Bridgeway Funds Inc-Ultra Small Company Market Fund0.15%21,000105.21KSep 29, 2024
iShares Micro Cap ETF0.14%18,94594.91KOct 30, 2024
Fidelity Total Market Index Fund0.13%17,94489.90KOct 30, 2024
Advertisement